Swiss chocolate maker Lindt & Sprüngli has reported an unexpected trend in consumer behavior: Americans using popular GLP-1 weight-loss medications are buying more chocolate rather than less.
The company revealed findings from an internal study indicating that users of these drugs are increasingly turning to premium chocolate products as occasional indulgences while cutting back on other high-calorie foods.
The study, based on February data from market research firm Circana, showed that approximately 15% of U.S. households are currently using GLP-1 medications.
Despite the appetite-suppressing effects of these drugs, these households accounted for about 17.5% of total chocolate sales in the United States, suggesting a disproportionately high demand for confectionery products among this group.
GLP-1 drugs—used primarily for weight management and diabetes treatment—include well-known medications such as Ozempic produced by Novo Nordisk and Mounjaro developed by Eli Lilly.
These medications are designed to regulate blood sugar levels and suppress appetite, often leading analysts to predict declining demand for calorie-dense foods like sweets and snacks.
However, Lindt’s recent data challenges those assumptions. According to the company, sales of premium chocolate among GLP-1 users in the United States rose by nearly 17% in 2025.
In comparison, chocolate purchases among non-users increased by only 6.5% during the same period.
Chief Executive Officer Adalbert Lechner explained that the change reflects a shift in consumer habits rather than a contradiction.
As people taking GLP-1 medications reduce their consumption of foods such as pizza, pasta, and potato chips, many still seek occasional treats.
Instead of frequent snacking, consumers appear to prefer smaller portions of higher-quality products.
“They are upgrading to premium products,” Lechner said during a press conference. “Less is more – small rewards with moments of bliss rather than mindless munching.”
The company believes this trend benefits premium confectionery brands.
Products such as Lindt’s iconic chocolate Easter bunnies and other high-end chocolates align with the idea of controlled indulgence – small portions enjoyed occasionally rather than large quantities consumed regularly.
Earlier forecasts from analysts had suggested that the growing popularity of GLP-1 medications could negatively impact the food and snack industry.
Analysts at investment bank Berenberg previously predicted that the expansion of GLP-1 treatments might reduce demand for confectionery products and potentially lower Lindt’s sales volumes by nearly one percentage point by 2027.
But Lindt’s latest findings suggest the reality may be more complex. Rather than eliminating demand for sweets, the medications may be reshaping how consumers approach indulgence.
Premiumization – where shoppers opt for higher-quality products in smaller quantities—appears to be a key factor behind rising chocolate sales among these consumers.
Looking ahead, Lindt expects the trend to continue as GLP-1 drugs become more widely available outside the United States.
Regulatory approvals for such medications in Europe are anticipated soon, and Lechner believes European consumers will display similar purchasing patterns.
Another factor likely to expand the market is the development of oral GLP-1 drugs.
Unlike current injectable treatments, pill-based versions are expected to appeal to a broader group of patients, including younger individuals and more men.
Because these oral medications are projected to produce less dramatic weight loss than injections, they may encourage a lifestyle approach that balances healthier eating with occasional indulgence.
For the confectionery industry, the findings offer reassurance that the rise of weight-loss medications may not signal the end of sweet treats.
Instead, companies like Lindt see an opportunity to position premium chocolates as small luxuries within increasingly health-conscious lifestyles.
